bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Movie 4 from Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors
Authors: Keddy Clare , Shinde Pushkar , Jones Kristen , Kaech Stefanie , Somwar Romel , Shinde Ujwal , Davare Monika A.
Published: April 2023

Supplementary Movie 4
Time-lapse movie of live confocal imaging.
Supplementary Figure from Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression
Authors: McGovern Karen , Castro Alfredo C. , Cavanaugh Jill , Coma Silvia , Walsh Meghan , Tchaicha Jeremy , Syed Sakeena , Natarajan Prabitha , Manfredi Mark , Zhang Xiaoyan M. , Ecsedy Jeffrey
Published: April 2023

Supplementary Figure from Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression
Supplementary Figure S5 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
Authors: Evans Rachel J. , Perkins Douglas W. , Selfe Joanna , Kelsey Anna , Birch Gavin P. , Shipley Janet M. , Schipper Koen , Isacke Clare M.
Published: April 2023

In vivo pilot experiment of NSG mice bearing MG-63 subcutaneous tumours treated intravenously with different concentrations of A5/158-vc-MMAE.
Supplementary Figure S3 from Endo180 (MRC2) Antibody–Drug Conjugate for the Treatment of Sarcoma
Authors: Evans Rachel J. , Perkins Douglas W. , Selfe Joanna , Kelsey Anna , Birch Gavin P. , Shipley Janet M. , Schipper Koen , Isacke Clare M.
Published: April 2023

Endo180 protein expression in sarcoma cell lines compared to epithelial cancer cells by immunofluorescence. Additionally, this figure shows the isotype control antibody conjugated to AlexaFluor 488 is not internalized into Endo180 expressing sarcoma cell lines and is not trafficked to the lysosome.
Supplementary Figures from Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer
Authors: Wildey Gary , Shay Ashley M. , McColl Karen S. , Yoon Suzy , Shatat Mohammad A. , Perwez Ahmad , Spainhower Kyle B. , Kresak Adam M. , Lipka MaryBeth , Yang Michael , Behtaj Mohadese , Fu Pingfu , Alahmadi Asrar , Mneimneh Wadad , Abbas Ata , Dowlati Afshin
Published: April 2023

Supplementary Figures
Supplementary Table S5 from ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs
Authors: Tsukamoto Shuntaro , Sugi Naoko Hata , Nishibata Kyoko , Nakazawa Youya , Ito Daisuke , Fukushima Sayo , Nakagawa Takayuki , Ichikawa Kenji , Kato Yu , Kakiuchi Dai , Goto Aya , Itoh-Yagi Machiko , Aota Tomoki , Inoue Satoshi , Yamane Yoshinobu , Murai Norio , Azuma Hiroshi , Nagao Satoshi , Sasai Ken , Akagi Tsuyoshi , Imai Toshio , Matsui Junji , Matsushima Tomohiro
Published: April 2023

Supplementary Data Table S5
Supplementary Data from Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
Authors: Darvishi Emad , Ghamsari Lila , Leong Siok F. , Ramirez Ricardo , Koester Mark , Gallagher Erin , Yu Miao , Mason Jody M. , Merutka Gene , Kappel Barry J. , Rotolo Jim A.
Published: April 2023

Supplementary Data from Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
Supplementary Data from Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer
Authors: Gregson Stephen J. , Pugh Kathryn , Patel Neki , Afif-Rider Shameen , Vijayakrishnan Balakumar , Santos Kathleen , Riedl Jitka , Hutchinson Ian , Kang Gyoung-Dong , Chooi K. Phin , Beard Rhiannon , Adams Lauren , Barry Conor S. , Ball Kathryn , Masterson Luke A. , McFarlane Mary , Hartley John A. , Howard Philip W.
Published: April 2023

Supplementary Data from Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer
Supplementary Data from Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models
Authors: Tran Khanh B. , Kolekar Sharada , Wang Qian , Shih Jen-Hsing , Buchanan Christina M. , Deva Sanjeev , Shepherd Peter R.
Published: April 2023

Supplementary Data from Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models
Suppl Figure 1 from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
Authors: Hsu Jeff , Chong Colin , Serrill Jeffrey , Goon Levina , Balayan Joan , Johnson Eric N. , Lorenzana Grachelle , Wu Sharon , Leong Kevin G. , Yun Theodore J. , Wang Yong , Jiang Faming , Bannen Lynne , Lamb Peter , Xu Wei , Yu Peiwen
Published: April 2023

Suppl Figure 1
Supplementary Figure from Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing Tumors
Authors: Scribner Juniper A. , Hicks Stuart W. , Sinkevicius Kerstin W. , Yoder Nicholas C. , Diedrich Gundo , Brown Jennifer G. , Lucas Jacquelynn , Fuller Megan E. , Son Thomas , Dastur Anahita , Hooley Jeff , Espelin Christopher , Themeles Marian , Chen Francine Z. , Li Ying , Chiechi Michael , Lee Jenny , Barat Bhaswati , Widjaja Lusiana , Gorlatov Sergey , Tamura James , Ciccarone Valentina , Ab Olga , McEachem Kerry A. , Koenig Scott , Westin Eric H. , Moore Paul A. , Chittenden Thomas , Gregory Richard J. , Bonvini Ezio , Loo Deryk
Published: April 2023

Supplementary Figure from Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody–drug Conjugate Targeting ADAM9-expressing Tumors
Supplementary Data from Combined Inhibition of Smoothened and the DNA Damage Checkpoint WEE1 Exerts Antitumor Activity in Cholangiocarcinoma
Authors: Anichini Giulia , Raggi Chiara , Pastore Mirella , Carrassa Laura , Maresca Luisa , Crivaro Enrica , Lottini Tiziano , Duwe Lea , Andersen Jesper B. , Tofani Lorenzo , Di Tommaso Luca , Banales Jesus M. , Arcangeli Annarosa , Marra Fabio , Stecca Barbara
Published: April 2023

Supplementary Data
Supplementary Table S4 from Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo
Authors: Jonchere Barbara , Williams Justin , Zindy Frederique , Liu Jingjing , Robinson Sarah , Farmer Dana M. , Min Jaeki , Yang Lei , Stripay Jennifer L. , Wang Yingzhe , Freeman Burgess B. , Yu Jiyang , Shelat Anang A. , Rankovic Zoran , Roussel Martine F.
Published: April 2023

Supplementary Table S4
Supplementary Table S1 from Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo
Authors: Jonchere Barbara , Williams Justin , Zindy Frederique , Liu Jingjing , Robinson Sarah , Farmer Dana M. , Min Jaeki , Yang Lei , Stripay Jennifer L. , Wang Yingzhe , Freeman Burgess B. , Yu Jiyang , Shelat Anang A. , Rankovic Zoran , Roussel Martine F.
Published: April 2023

Supplementary Table S1
Data from Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma
Authors: Shackleford Terry J. , Hariharan Seethalakshmi , Vaseva Angelina V. , Alagoa Karina , Espinoza Maricruz , Bid Hemant K. , Li Fuyang , Zhong Haihong , Phelps Doris A. , Roberts Ryan D. , Cam Hakan , London Cheryl A. , Guttridge Denis C. , Chen Yidong , Rao Manjeet , Shiio Yuzuru , Houghton Peter J.
Published: April 2023

Abstract
Antibodies targeting insulin-like growth factor 1 receptor (IGF-1R) induce objective responses in only 5% to 15% of children with sarcoma. Understanding the mechanisms of resistance may identify combination therapies that optimize efficacy of IGF-1R–targeted antibodies. Sensitivity to the IGF-1R–targeting antibody TZ-1 was determined in rhabdomyosarcoma and Ewing sarcoma cell lines. Acquired resistance to TZ-1 was developed and characterized in sensitive Rh41 cells. The BRD4 inhibitor, JQ1, was evaluated as an agent to prevent acquired TZ-1 resistance in Rh41 cells. The phosphorylation status of receptor tyrosine kinases (RTK) was assessed. Sensitivity to TZ-1 in vivo was determined in Rh41 parental and TZ-1–resistant xenografts. Of 20 sarcoma cell lines, only Rh41 was sensitive to TZ-1. Cells intrinsically resistant to TZ-1 expressed multiple (>10) activated RTKs or a relatively less complex set of activated RTKs (∼5). TZ-1 decreased the phosphorylation of IGF-1R but had little effect on other phosphorylated RTKs in all resistant lines. TZ-1 rapidly induced activation of RTKs in Rh41 that was partially abrogated by knockdown of SOX18 and JQ1. Rh41/TZ-1 cells selected for acquired resistance to TZ-1 constitutively expressed multiple activated RTKs. TZ-1 treatment caused complete regressions in Rh41 xenografts and was significantly less effective against the Rh41/TZ-1 xenograft. Intrinsic resistance is a consequence of redundant signaling in pediatric sarcoma cell lines. Acquired resistance in Rh41 cells is associated with rapid induction of multiple RTKs, indicating a dynamic response to IGF-1R blockade and rapid development of resistance. The TZ-1 antibody had greater antitumor activity against Rh41 xenografts compared with other IGF-1R–targeted antibodies tested against this model.
Data from Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody–Drug Conjugates
Authors: Bordeau Brandon M. , Nguyen Toan Duc , Polli Joseph Ryan , Chen Ping , Balthasar Joseph P.
Published: April 2023

Abstract
Monomethyl auristatin E (MMAE) is a potent tubulin inhibitor that is used as the payload for four FDA-approved antibody–drug conjugates (ADC). Deconjugated MMAE readily diffuses into untargeted cells, resulting in off-target toxicity. Here, we report the development and evaluation of a humanized Fab fragment (ABC3315) that enhances the therapeutic selectivity of MMAE ADCs. ABC3315 increased the IC50 of MMAE against human cancer cell lines by > 500-fold with no impact on the cytotoxicity of MMAE ADCs, including polatuzumab vedotin (PV) and trastuzumab-vc-MMAE (TvcMMAE). Coadministration of ABC3315 did not reduce the efficacy of PV or TvcMMAE in xenograft tumor models. Coadministration of ABC3315 with 80 mg/kg TvcMMAE significantly (P < 0.0001) increased the cumulative amount of MMAE that was excreted in urine 0 to 4 days after administration from 789.4±19.0 nanograms (TvcMMAE alone) to 2625±206.8 nanograms (for mice receiving TvcMMAE with coadministration of ABC3315). Mice receiving 80 mg/kg TvcMMAE and PBS exhibited a significant drop in white blood cell counts (P = 0.025) and red blood cell counts (P = 0.0083) in comparison with control mice. No significant differences, relative to control mice, were found for white blood cell counts (P = 0.15) or for red blood cell counts (P = 0.23) for mice treated with 80 mg/kg TvcMMAE and ABC3315. Coadministration of ABC3315 with 120 mg/kg PV significantly (P = 0.045) decreased the percentage body weight loss at nadir for treated mice from 11.9%±7.0% to 4.1%±2.1%. Our results demonstrate that ABC3315, an anti-MMAE Fab fragment, decreases off-target toxicity while not decreasing antitumor efficacy, increasing the therapeutic window of MMAE ADCs.
Abstract 3868: Aurora kinase A inhibition overcome adaptive resistance to KRAS G12C inhibitor by G1-checkpoint induced apoptosis in KRAS non-small cell lung cancer
Authors: Li Chendi , Chang Jeremy , Syed Mohammed U. , Nimbalkar Anahita , Shen Yi , Altschuler Steve , Wu Lani , Gong Xueqian , Hata Aaron
Published: April 2023

Cancer cells gain drug-tolerant states and evade therapy. In response to KRAS G12C inhibitor (G12Ci), KRAS mutant non-small cell lung cancer (NSCLC) cells maintain a drug-tolerant state by aurora kinase A (AURKA). AURKA can phosphorylate c-Raf to maintain new KRAS signaling, however, how AURKA becomes activated to cause KRAS G12Ci resistance is unclear. We show here that KRAS G12C + AURKA inhibition cause synthetic lethality in KRAS G12C NSCLC cells. LY3499446 (KRAS G12Ci) and LSN3321213 (aurora kinase A inhibitor) induced apoptosis that is independent of inhibited MAPK reactivation. Using high-content imaging that tracks single-cell fate during treatment, we observed that single-agent KRAS G12Ci induces G1 arrest in a sub-population of cells. Upon co-treatment with G12C + AURKAi, cells that are halted in G1 phase undergo early apoptosis, while those that initially evade G1 arrest and proceed through G2/M undergo apoptosis in subsequent G1. These data suggest the hypothesis that AURKA inhibition may increase the probability of G1 checkpoint-induced apoptosis by facilitating chromosomal misalignment and genomic instability. In summary, we provide clinical rationale for clinical testing of KRAS G12C + AURKA inhibitors. We also suggest a novel mechanism explaining the dependency of KRAS G12C resistant subpopulations on AURKA, leading to the opportunity to investigate the role of genomic instability in conferring KRAS G12Ci adaptive resistance.

Citation Format: Chendi Li, Jeremy Chang, Mohammed U. Syed, Anahita Nimbalkar, Yi Shen, Steve Altschuler, Lani Wu, Xueqian Gong, Aaron Hata. Aurora kinase A inhibition overcome adaptive resistance to KRAS G12C inhibitor by G1-checkpoint induced apoptosis in KRAS non-small cell lung cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3868.
Abstract 4305: Germline structural variants shape prostate cancer clinical and molecular evolution
Authors: Wang Nicholas K. , Rouette Alexandre , Houlahan Kathleen E. , Yamaguchi Takafumi N. , Livingstone Julie , Jung Chol-Hee , Georgeson Peter , Fraser Michael , Shiah Yu-Jia , Yao Cindy Q. , Huang Vincent , Fox Natalie S. , Kurganovs Natalie , Kasaian Katayoon , Sabelnykova Veronica Y. , Jayalath Jay , Weke Kenneth , Zhu Helen , van der Kwast Theodorus , Papenfuss Tony , He Housheng H. , Corcoran Niall M. , Bristow Robert G. , Zlotta Alexandre R. , Hovens Christopher , Boutros Paul C.
Published: April 2023

Inherited genetic variation profoundly influences cancer risk and outcome. While the impact of germline single nucleotide polymorphisms has been well-studied in several cancer types, the effects of germline structural variants (gSVs) on cancer biology and clinical outcomes is largely unknown. From our cohort of 300 men with localized, intermediate risk prostate cancer, we identified 6,003 gSVs present in at least 3% of patients; 48 were associated with recurrent somatic alterations or clinical outcome. Of these, approximately 50% were associated with expression of nearby genes or intersected with exons or regulatory regions. Using external cohorts, we validated three gSVs that were strongly associated with poor clinical outcomes, including an inversion at chr14q24.1 present in ~20% of patients. Notably, a strong synergistic effect on outcome was observed in patients with somatic TP53 alterations or high genomic instability, defining a new aggressive prostate cancer subtype with chr14INV as a novel, recurrent biomarker.

Citation Format: Nicholas K. Wang, Alexandre Rouette, Kathleen E. Houlahan, Takafumi N. Yamaguchi, Julie Livingstone, Chol-Hee Jung, Peter Georgeson, Michael Fraser, Yu-Jia Shiah, Cindy Q. Yao, Vincent Huang, Natalie S. Fox, Natalie Kurganovs, Katayoon Kasaian, Veronica Y. Sabelnykova, Jay Jayalath, Kenneth Weke, Helen Zhu, Theodorus van der Kwast, Tony Papenfuss, Housheng H. He, Niall M. Corcoran, Robert G. Bristow, Alexandre R. Zlotta, Christopher Hovens, Paul C. Boutros. Germline structural variants shape prostate cancer clinical and molecular evolution. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4305.
Abstract 5800: Anti-metastatic potential of pitavastatin in triple-negative breast cancer via targeting breast cancer stem-like properties and STAT3 signaling
Authors: Ko Dongmi , Seo Juyeon , Kim Seongjae , Park Soeun , Park Minsu , Nam Kee Dal , Kang Yong koo , Seock Sora , Jung Eunsun , Kim Yoon-Jae , Park Jaeyoun , Kim Ji Young , Seo Jae Hong
Published: April 2023

Triple-negative breast cancer (TNBC) is the most deadly and aggressive phenotype, with a higher rate of metastatic recurrence. TNBC does yet have a suitable treatment option other than cytotoxic anticancer drugs. Although pitavastatin has been shown to exert anti-proliferative effects and cytotoxicity in various types of cancer cells, the precise mechanisms underlying pitavastatin’s anti-cancer effects in TNBC have not been fully elucidated. We sought to investigate the mechanism of pitavastatin-induced apoptosis and its effects on cancer stem cell (CSC)-like characteristics in TNBC. Exposure to pitavastatin induced mitochondria-mediated apoptotic cell death in BT549 and 4T1 cells. Mitochondrial dysfunction was accompanied with a robust production of reactive oxygen species (ROS) and collapse of mitochondrial membrane potential (MMP), resulting in subsequent activation of caspase-3/-7 and PARP cleavage. Pitavastatin effectively suppressed CSC-like properties in TNBC via targeting CD44+/CD24- and CD49f+/CD24- phenotypes, as well as impediment of mammosphere formation in vitro. This phenomenon was accompanied with dysregulation of STAT3 survival pathway, concomitant with significant downregulation of cyclin D1, survivin and vimentin. Pitavastatin effectively targets both the proliferating TNBC tumor cells and CSCs via the dysregulation of STAT3 and suppression of CSC-like properties, markedly reducing angiogenesis and tumor growth, coinciding with decreased Ki-67 expression. It is noteworthy that pitavastatin considerably suppressed metastasis, coinciding with significant reduction of MMP-2, MMP-9 and VEGF in the circulating blood of mice. Our findings highlight that pitavastatin may be potentially effective for the treatment of metastatic TNBC.

Citation Format: Dongmi Ko, Juyeon Seo, Seongjae Kim, Soeun Park, Minsu Park, Kee Dal Nam, Yong koo Kang, Sora Seock, Eunsun Jung, Yoon-Jae Kim, Jaeyoun Park, Ji Young Kim, Jae Hong Seo. Anti-metastatic potential of pitavastatin in triple-negative breast cancer via targeting breast cancer stem-like properties and STAT3 signaling. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5800.
Supplementary Figures 1-6 and Tables 1-2 from Menin Directly Represses Gli1 Expression Independent of Canonical Hedgehog Signaling
Authors: Gurung Buddha , Feng Zijie , Hua Xianxin
Published: April 2023

PDF - 2205KB, Supplementary Figure 1: Gli1 mRNA levels in menin-null cells complemented with physiologically relevant Men1 mutants. Men1-null MEF's were complemented with either vector, WT, or the mutant A242V and the levels of Gli1 were determined by qRT-PCR. Data was normalized to Men1-null cells complemented with WT menin. Supplementary Figure 2: Gli1 mRNA levels are elevated upon Men1 excision in MEFs. Men1l/l;Ubc9 CreER cells were treated with either DMSO or 4-hydroxy tamoxifen (4-OHT)and the levels of Gli1 were determined by qRT-PCR. Inset, Western Blotting showing complete excision of menin upon 4-OHT treatment. Data were normalized to Gli1 values in DMSO treated cells. Supplementary Figure 3: Ectopic expression of menin results in reduction of Gli1 in BON cells, a human carcinoid cell line. qRT-PCR for Gli1 mRNA in BON cells ectopically expressing menin or control vector. Inset, Western blotting of menin in BON cells ectopically expressing menin or control vector.Supplementary Figure 4: Chromatin IP (ChIP) for total histone H3 in PIME1 cells treated with either DMSO (Men1l/l) or tamoxifen (Men1Δ/Δ). Supplementary Figure 5: Total HDAC1 level are unaffected upon Men1 excision. Cell lysates from Men1l/l;CreER MEFs treated with either DMSO (lane 1) or tamoxifen (lane 2), and PIME cells treated with either DMSO (lane 3 ) or tamoxifen (lane 4) were subjected to SDS-PAGE and immunoblotted for HDAC1. Ponceau S is included as a loading control. Supplementary Figure 6: Quantitation of C-MYC and PTCH1 protein levels in menin-null PIME1 cells treated with GANT-61. Cell lysates from menin-null PIME1 cells treated with either DMSO or GANT-61 were immunoblotted with anti-MYC and anti-PTCH1 antibodies, and the band intensities were quantitated by densitometeric analysis using Image J software and normalized to the intensity of their respective Ponceau S stains. Data are normalized to DMSO-treated cells. Supplementary Table 1: qRT-PCR primers. Supplementary Table 2: ChIP primers
Supplementary Table 1 from Alpha-CaMKII Plays a Critical Role in Determining the Aggressive Behavior of Human Osteosarcoma
Authors: Daft Paul G. , Yuan Kaiyu , Warram Jason M. , Klein Michael J. , Siegal Gene P. , Zayzafoon Majd
Published: April 2023

Supplementary Table 1 PDF file - 64K, Association of p-�-CaMKII IHC staining with osteosarcoma subtypes compared to normal bone
Supplementary Figure 2 from PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality
Authors: Bluemn Eric G. , Spencer Elysia Sophie , Mecham Brigham , Gordon Ryan R. , Coleman Ilsa , Lewinshtein Daniel , Mostaghel Elahe , Zhang Xiaotun , Annis James , Grandori Carla , Porter Christopher , Nelson Peter S.
Published: April 2023

PDF, 269K, Localization of PPP2R2C in LNCaP and VCaP cells.
Supplemental Table 1 from A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function
Authors: Menezes Daniel L. , Holt Jenny , Tang Yan , Feng Jiajia , Barsanti Paul , Pan Yue , Ghoddusi Majid , Zhang Wei , Thomas George , Holash Jocelyn , Lees Emma , Taricani Lorena
Published: April 2023

Supplemental Table 1. DiscoveRx ATR inhibitor profile
Supplementary Figure 5 from Inhibition of the ATR–CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2
Authors: Koppenhafer Stacia L. , Goss Kelli L. , Terry William W. , Gordon David J.
Published: April 2023

Supplementary Figure 5 shows a Loewe matrix plot for VX-970 and AZD1775.
Supplementary Table S1 from Potent Antineoplastic Effects of Combined PI3Kα–MNK Inhibition in Medulloblastoma
Authors: Eckerdt Frank , Bell Jonathan B. , Beauchamp Elspeth M. , Clymer Jessica , Blyth Gavin T. , Kosciuczuk Ewa M. , Ma Quanhong , Chen David Z. , Horbinski Craig , Goldman Stewart , Munshi Hidayatullah G. , Hashizume Rintaro , Platanias Leonidas C.
Published: April 2023

Pairwise tests for differences in stem cell frequencies.
Supplemental Methods from Pattern-Specific Transcriptomics Identifies ASGR2 as a Predictor of Hematogenous Recurrence of Gastric Cancer
Authors: Tanaka Haruyoshi , Kanda Mitsuro , Miwa Takashi , Tanaka Chie , Kobayashi Daisuke , Umeda Shinichi , Shibata Masahiro , Suenaga Masaya , Hattori Norifumi , Hayashi Masamichi , Iwata Naoki , Yamada Suguru , Nakayama Goro , Fujiwara Michitaka , Kodera Yasuhiro
Published: April 2023

Supplemental Methods
Authorship Change Form from Adaptation to HIF1α Deletion in Hypoxic Cancer Cells by Upregulation of GLUT14 and Creatine Metabolism
Authors: Valli Alessandro , Morotti Matteo , Zois Christos E. , Albers Patrick K. , Soga Tomoyoshi , Feldinger Katharina , Fischer Roman , Frejno Martin , McIntyre Alan , Bridges Esther , Haider Syed , Buffa Francesca M. , Baban Dilair , Rodriguez Miguel , Yanes Oscar , Whittington Hannah J. , Lake Hannah A. , Zervou Sevasti , Lygate Craig A. , Kessler Benedikt M. , Harris Adrian L.
Published: April 2023

S8. WTN, KON, WTH, and KOH HCT116 cell proliferation after 5 days in two O2 conditions,21% and 1% for cells knocked down for GTR3, GTR14 , and HIF2α
Supplementary Figures S1~S7, Tables S1 and S2 from Functional Analysis of Aberrantly Spliced Caspase8 Variants in Adult T-Cell Leukemia Cells
Authors: Nakano Kazumi , Iwanaga Masako , Utsunomiya Atae , Uchimaru Kaoru , Watanabe Toshiki
Published: April 2023

Figure S1. Primary structures of Casp8 isoforms. Figure S2. Replicated results in the CASP8 mRNA alternative splicing reporter assay. Figure S3. Apoptosis assays in EGFP-Casp8 expressing cells. Figure S4. Condensed structures and death effector filament (DEF) formations by Casp8L and Casp8-Î"E7. Figure S5. The sub-cellular localization of RelA in HEK293FT cells overexpressing mCherry-Casp8 isoforms. Figure S6. The sub-cellular localization of RelA in Jurkat cells overexpressing mCherry-Casp8 isoforms. Figure S7. Destruction of DEFs by F122G/L123G mutagenesis in EGFP-Casp8L and EGFP-Casp8-Î"E7. Table S1. Primary sample information Table S2. Realtime-PCR primers for CASP8 mRNA variants
Supplementary Figure Legends, Figures 1 - 7 from Integration of Distinct ShcA Signaling Complexes Promotes Breast Tumor Growth and Tyrosine Kinase Inhibitor Resistance
Authors: Ha Jacqueline R. , Ahn Ryuhjin , Smith Harvey W. , Sabourin Valerie , Hébert Steven , Cepeda Cañedo Eduardo , Im Young Kyuen , Kleinman Claudia L. , Muller William J. , Ursini-Siegel Josie
Published: April 2023

Supplementary Figure Legends, Figures 1 - 7 from Integration of Distinct ShcA Signaling Complexes Promotes Breast Tumor Growth and Tyrosine Kinase Inhibitor Resistance
Supplemental Figures and Legends 1 - 6 from Intrinsic Resistance to MEK Inhibition through BET Protein–Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer
Authors: Kurimchak Alison M. , Shelton Claude , Herrera-Montávez Carlos , Duncan Kelly E. , Chernoff Jonathan , Duncan James S.
Published: April 2023

Supplemental Figure 1. MEK inhibition has minimal impact on cell viability in the majority of NF1-deficient cell lines. Supplemental Figure 2. MEK inhibition induces transcription of several RTKs in EOC cell lines. Supplemental Figure 3. Co-targeting RTK, RAF or PI3K enhanced growth inhibition of trametinib in EOC cells. Supplemental Figure 4. MEKi-mediated destabilization of FOSL1 promotes RTK upregulation in JHOS-2 NF1-defecient cells. Supplemental Figure 5. BET bromodomain proteins mediate MEKi-resistance in NF1-deficient A1847 cells. Supplemental Figure 6. Co-targeting BET and MEK proteins overcomes MEKi-resistance due to kinome reprogramming in NF1-deficient cells providing more durable response.
Table S3 from Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress–Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer
Authors: Bagheri-Yarmand Rozita , Sinha Krishna M. , Li Ling , Lu Yue , Cote Gilbert J. , Sherman Steven I. , Gagel Robert F.
Published: April 2023

Primers used for ChIP sequencing validation.
Figure S3 from Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer
Authors: Das Lipsa , Gard Jaime M.C. , Prekeris Rytis , Nagle Raymond B. , Morrissey Colm , Knudsen Beatrice S. , Miranti Cindy K. , Cress Anne E.
Published: April 2023

Supplementary Figure 3. Recycling kinetics and cell membrane expression of β4 integrin in Rab11-FIP5 depleted cells. DU145 cells were transfected with non-targeting siRNA (siCon), and siRNA against Rab11-FIP5 (siFIP5) or α6 integrin (siα6). (A) Recycling kinetic curve for β4 integrin in untreated and siFIP5 DU145 cells. Percent label recycled to the cell surface at 25{degree sign}C (calculated as percent mean peak fluorescence of recycled label at a given timepoint vs total label internalized) is plotted for different time intervals. First order kinetic curve is fitted (R2>0.98). (B) Maximum label recycled (%) and recycling rate constants (observed, kobs and actual, kactual) calculated as per first order rate kinetics. Results represent 5 independent experiments. Statistical significance calculated for changes in label recycled at each timepoint and maximum label recycled as per student's t-test, unpaired, **p<0.01, n=5. (C) Flow histogram (top) and relative mean peak fluorescence of cell surface expression of β4 integrin assessed by immunolabelling in fixed, non-permeabilized untreated (shaded solid line), siCon (solid line), siFIP5 (dashed line) and siα6 (dotted line) cells (**p<0.01, n=5).
Figure S3 from Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress–Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer
Authors: Bagheri-Yarmand Rozita , Sinha Krishna M. , Li Ling , Lu Yue , Cote Gilbert J. , Sherman Steven I. , Gagel Robert F.
Published: April 2023

Ingenuity Pathway Analysis of ATF4 target genes
Table S1. Immunosuppressive Pathways Decreased Following miR-200c Restoration from Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression
Authors: Rogers Thomas J. , Christenson Jessica L. , Greene Lisa I. , O'Neill Kathleen I. , Williams Michelle M. , Gordon Michael A. , Nemkov Travis , D'Alessandro Angelo , Degala Greg D. , Shin Jimin , Tan Aik-Choon , Cittelly Diana M. , Lambert James R. , Richer Jennifer K.
Published: April 2023

Extended list of genes associated with enriched immunosuppressive pathways following GSEA analysis in BT549-TripZ-200c cells following miR-200c restoration.
Supplementary Figure 2 from Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression
Authors: Rogers Thomas J. , Christenson Jessica L. , Greene Lisa I. , O'Neill Kathleen I. , Williams Michelle M. , Gordon Michael A. , Nemkov Travis , D'Alessandro Angelo , Degala Greg D. , Shin Jimin , Tan Aik-Choon , Cittelly Diana M. , Lambert James R. , Richer Jennifer K.
Published: April 2023

Expanded GSEA results following miR-200c restoration in TNBC cells.
Supplementary Table S1 from Divergent Activity of the Pseudogene PTENP1 in ER-Positive and Negative Breast Cancer
Authors: Yndestad Synnøve , Austreid Eilin , Skaftnesmo Kai Ove , Lønning Per Eystein , Eikesdal Hans Petter
Published: April 2023

Summary of baseline characteristics and results for breast cancer cell lines tested.
Supplementary Figure S2 from Divergent Activity of the Pseudogene PTENP1 in ER-Positive and Negative Breast Cancer
Authors: Yndestad Synnøve , Austreid Eilin , Skaftnesmo Kai Ove , Lønning Per Eystein , Eikesdal Hans Petter
Published: April 2023

Supplementary Figure S2
Figure S4 from Novel Aberrations Uncovered in Barrett's Esophagus and Esophageal Adenocarcinoma Using Whole Transcriptome Sequencing
Authors: Maag Jesper L.V. , Fisher Oliver M. , Levert-Mignon Angelique , Kaczorowski Dominik C. , Thomas Melissa L. , Hussey Damian J. , Watson David I. , Wettstein Antony , Bobryshev Yuri V. , Edwards Melanie , Dinger Marcel E. , Lord Reginald V.
Published: April 2023

Supplementary figure 4. Esophageal adenocarcinoma cell line viability changes after shRNA knockdown of 21 genes identified through network and machine learning analysis, and Representative IHC staining slides of the 4-gene signature. (a) Two esophageal cancer cell lines, JHESOAD1 and OE33 were interrogated through the Broad Institute Project Achilles for changes in viability after pooled shRNA mediated gene knockdown. Y-axis measures relative change in cell viability. (b) Comparison of the effect of knockdowns of genes of interest on different GI cell types from the Achilles data base. (c) Representative slides from the IHC staining between NE, NDBE, and EAC, NDBE and EAC slides from COL17A1 and from E2F3 are the same as in Figure 3f.
Supplementary Tables 1 - 7 from Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
Authors: Arend Rebecca C. , Londoño Angelina I. , Montgomery Allison M. , Smith Haller J. , Dobbin Zachary C. , Katre Ashwini A. , Martinez Alba , Yang Eddy S. , Alvarez Ronald D. , Huh Warner K. , Bevis Kerri S. , Straughn J. Michael , Estes Jacob M. , Novak Lea , Crossman David K. , Cooper Sara J. , Landen Charles N. , Leath Charles A.
Published: April 2023

Table 1. Tumor Histology, Cellularity, and Chemotherapy Respons. Table 2. Significance and Fold Change of 770 genes and corresponding pathways in pre- and post-NACT. Table 3. List of top canonical pathways, molecular and cellular function, toxicity list, and networks. Table 4. Classification of all variants identified in DNA and cell-free DNA of pre- and post-NACT. Protein Change. Table 5. Number of mutant genes and specific variants in pre- and post-NAC. Table 6. All variants in pre- and post-NACT and recurrent plasma samples.Table 7. Potential FDA-approved targeted therapies and clinical trials based on gene level alterations.
Supplementary Table S2 from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
Authors: Salem Mohamed E. , Puccini Alberto , Grothey Axel , Raghavan Derek , Goldberg Richard M. , Xiu Joanne , Korn W. Michael , Weinberg Benjamin A. , Hwang Jimmy J. , Shields Anthony F. , Marshall John L. , Philip Philip A. , Lenz Heinz-Josef
Published: April 2023

Comparison between percentages of PD-L1 positive tumors using the cut-off at >5% (as in our analysis) and the cut-off >1% (as FDA-approved test for pembrolizumab use in advanced gastric and gastroesophageal junction adenocarcinomas).
Supplementary Table S1 from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
Authors: Salem Mohamed E. , Puccini Alberto , Grothey Axel , Raghavan Derek , Goldberg Richard M. , Xiu Joanne , Korn W. Michael , Weinberg Benjamin A. , Hwang Jimmy J. , Shields Anthony F. , Marshall John L. , Philip Philip A. , Lenz Heinz-Josef
Published: April 2023

PD-L1 expression frequency comparison between MSI-H and MSS tumors.
Figure S3 from Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers
Authors: Wilson Timothy R. , Udyavar Akshata R. , Chang Ching-Wei , Spoerke Jill M. , Aimi Junko , Savage Heidi M. , Daemen Anneleen , O'Shaughnessy Joyce A. , Bourgon Richard , Lackner Mark R.
Published: April 2023

Enriched Pathway Analysis.
Supplementary Figure 3 from Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent
Authors: Sizemore Steven T. , Mohammad Rahman , Sizemore Gina M. , Nowsheen Somaira , Yu Hao , Ostrowski Michael C. , Chakravarti Arnab , Xia Fen
Published: April 2023

Western blots demonstrating knockdown of endogenous p53 and expression of exogenous R273H mutant p53.
Supplementary Figure 6. (A) from Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of BRCA1 BRCT Variants on Cancer Risk
Authors: Petitalot Ambre , Dardillac Elodie , Jacquet Eric , Nhiri Naima , Guirouilh-Barbat Josée , Julien Patrick , Bouazzaoui Isslam , Bonte Dorine , Feunteun Jean , Schnell Jeff A. , Lafitte Philippe , Aude Jean-Christophe , Noguès Catherine , Rouleau Etienne , Lidereau Rosette , Lopez Bernard S. , Zinn-Justin Sophie , Caputo Sandrine M.
Published: April 2023

FBTSA assay revealing that binding of the WT BRCA1 BRCT domains to ACC1-P, BACH1-P, CtiP-P, AB-1P and AB-2P induce a measurable increase in the BRCT thermostability that raises with peptide concentration.
Table S1 from The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 Inhibition
Authors: Ishida Ryo , Koyanagi-Aoi Michiyo , Oshima Nobu , Kakeji Yoshihiro , Aoi Takashi
Published: April 2023

Microarray Probe List
Supplementary Text from The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 Inhibition
Authors: Ishida Ryo , Koyanagi-Aoi Michiyo , Oshima Nobu , Kakeji Yoshihiro , Aoi Takashi
Published: April 2023

RNA isolation and quantitative reverse-transcriptase polymerase chain reaction
Supplementary Video 2 from Adaptive Resistance to EGFR-Targeted Therapy by Calcium Signaling in NSCLC Cells
Authors: Mulder Celine , Prust Nadine , van Doorn Sander , Reinecke Maria , Kuster Bernhard , van Bergen en Henegouwen Paul , Lemeer Simone
Published: April 2023

Supplementary Video 2
Supplementary Figure 1 from The Lymphotactin Receptor Is Expressed in Epithelial Ovarian Carcinoma and Contributes to Cell Migration and Proliferation
Authors: Kim Mijung , Rooper Lisa , Xie Jia , Rayahin Jamie , Burdette Joanna E. , Kajdacsy-Balla Andre A. , Barbolina Maria V.
Published: April 2023

PDF file - 21K, Alignment of XCL1 (NM_002995) and XCL2 (NM_003175) gene sequences using NCBI BLAST (NIH). Nucleotides that do not match are highlighted in yellow. Positions of the sequences used to construct primers for detection of XCL1 and XCL2 are indicated by blue arrows.
Supplementary Figures 1-4 from Disseminated Prostate Cancer Cells Can Instruct Hematopoietic Stem and Progenitor Cells to Regulate Bone Phenotype
Authors: Joseph Jeena , Shiozawa Yusuke , Jung Younghun , Kim Jin Koo , Pedersen Elisabeth , Mishra Anjali , Zalucha Janet Linn , Wang Jingcheng , Keller Evan T. , Pienta Kenneth J. , Taichman Russell S.
Published: April 2023

PDF file - 1MB
Supplementary Table 3 from The Signal Peptide of Mouse Mammary Tumor Virus-Env: A Phosphoprotein Tumor Modulator
Authors: Feldman Dafna , Roniger Maayan , Bar-Sinai Allan , Braitbard Ori , Natan Carmit , Love Dona C. , Hanover John A. , Hochman Jacob
Published: April 2023

XLS file - 23K, 142 genes which are transcriptionally regulated (up, down) by the PKC- vs CK2- mutant p14s
Supplementary Figures S1-S3 from Localization of Fas/CD95 into the Lipid Rafts on Down-Modulation of the Phosphatidylinositol 3-Kinase Signaling Pathway
Authors: Bénéteau Marie , Pizon Mathieu , Chaigne-Delalande Benjamin , Daburon Sophie , Moreau Patrick , De Giorgi Francesca , Ichas François , Rebillard Amélie , Dimanche-Boitrel Marie-Thérèse , Taupin Jean-Luc , Moreau Jean-François , Legembre Patrick
Published: April 2023

Supplementary Figures S1-S3 from Localization of Fas/CD95 into the Lipid Rafts on Down-Modulation of the Phosphatidylinositol 3-Kinase Signaling Pathway
Supplementary Methods from Ligand Binding Promotes CDK-Dependent Phosphorylation of ER-Alpha on Hinge Serine 294 but Inhibits Ligand-Independent Phosphorylation of Serine 305
Authors: Held Jason M. , Britton David J. , Scott Gary K. , Lee Elbert L. , Schilling Birgit , Baldwin Michael A. , Gibson Bradford W. , Benz Christopher C.
Published: April 2023

PDF file - 131K
Supplementary Figure Legend from Suppression of G-protein–Coupled Receptor Kinase 3 Expression Is a Feature of Classical GBM That Is Required for Maximal Growth
Authors: Woerner B. Mark , Luo Jingqin , Brown Kristin R. , Jackson Erin , Dahiya Sonika M. , Mischel Paul , Benovic Jeffrey L. , Piwnica-Worms David , Rubin Joshua B.
Published: April 2023

PDF file - 66KB
Supplementary Figure 1 from Suppression of G-protein–Coupled Receptor Kinase 3 Expression Is a Feature of Classical GBM That Is Required for Maximal Growth
Authors: Woerner B. Mark , Luo Jingqin , Brown Kristin R. , Jackson Erin , Dahiya Sonika M. , Mischel Paul , Benovic Jeffrey L. , Piwnica-Worms David , Rubin Joshua B.
Published: April 2023

PDF file - 4786KB
Supplementary Table 2 from N-myc and Noncoding RNAs in Neuroblastoma
Authors: Buechner Jochen , Einvik Christer
Published: April 2023

PDF file - 86K, Correlation between miRNA and N�myc expression in NB cell lines
Supplementary Table 1 from Role of WNT7B-induced Noncanonical Pathway in Advanced Prostate Cancer
Authors: Zheng Dali , Decker Keith F. , Zhou Tianhua , Chen Jianquan , Qi Zongtai , Jacobs Kathryn , Weilbaecher Katherine N. , Corey Eva , Long Fanxin , Jia Li
Published: April 2023

PDF file - 50K, Primer sequences
Supplementary Table 1 from N-myc and Noncoding RNAs in Neuroblastoma
Authors: Buechner Jochen , Einvik Christer
Published: April 2023

PDF file - 62K, Differentially expressed miRNAs between MNA and non�MNA primary tumors
Supplementary Table 3 from Analysis of mRNA Profiles after MEK1/2 Inhibition in Human Pancreatic Cancer Cell Lines Reveals Pathways Involved in Drug Sensitivity
Authors: Gysin Stephan , Paquette Jesse , McMahon Martin
Published: April 2023

PDF file, 46K, Top 50 regulated mRNAs in least MEK inhibitor sensitive cell lines.
Supplementary Figure 2 from Protein Kinase Casein Kinase 2–Mediated Upregulation of N-Cadherin Confers Anoikis Resistance on Esophageal Carcinoma Cells
Authors: Ko Hyeonseok , Kim Seongrak , Jin Cheng-Hao , Lee Eunjung , Ham Sunyoung , Yook Jong In , Kim Kunhong
Published: April 2023

PDF file - 59K, PKCK2 activity dependent stabilization of exogenous Snail. A, MCF-7 cells that have low PKCK2 activity were co-transfected with Flag tagged Snail expression vector along either with empty vector or with Myc tagged PKCK2� expression vector. B, HCE4 cells were transfected with Flag-Snail and then were treated or un-treated with TBB, a pharmacologic inhibitor of PKCK2. C, PKCK2 activity was measured for each condition. S92 represents a vector expressing wild type snail, S92A (serine 92 replaced with alanine) mutant represents a vector expressing non-phosphorylatable form of snail, and S92E (serine 92 replaced with glutamic acid) represents a vector expressing mutant snail to mimic constitutive phosphorylation
Supplementary Figures 1-6, Tables 1-2, Methods from A Novel Function of YWHAZ/β-Catenin Axis in Promoting Epithelial–Mesenchymal Transition and Lung Cancer Metastasis
Authors: Chen Ching-Hsien , Chuang Show-Mei , Yang Meng-Fang , Liao Jiunn-Wang , Yu Sung-Liang , Chen Jeremy J.W.
Published: April 2023

PDF file - 354K, Supplementary data, supplementary methods and supplementary references S1. YWHAZ expression promotes tumor growth. S2. YWHAZ induces cell protrusion and branching formation. S3. Analysis of beta-catenin stability in the mock and YWHAZ transfectants of CL1-0 cells. S4. YWHAZ overexpression reduces the interaction of beta-catenin with Myc-tagged ubiquitin. S5. Confirmation of the cytosolic interaction between YWHAZ and beta-catenin. S6. Effects of endogenous beta-catenin Ser552 phosphorylation on its interaction with endogenous YWHAZ. Table S1. Summary of pathological incidence of lungs in mice by intravenous injection with YWHAZ-expressing cells or mock control. Table S2. Comparison of the incidence of tumorigenesis or metastasis between mock and YWHAZ transfectant in SCID mice by orthotopic lung implantation model.
Table S1 from Clinically Relevant microRNAs in Ovarian Cancer
Authors: Zhang Shu , Lu Zhen , Unruh Anna K. , Ivan Cristina , Baggerly Keith A. , Calin George A. , Li Zongfang , Bast Robert C. , Le Xiao-Feng
Published: April 2023

Table S1. Differentially expressed genes.
Supplemental Figure 4 from Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma
Authors: Newman Erika A. , Lu Fujia , Bashllari Daniela , Wang Li , Opipari Anthony W. , Castle Valerie P.
Published: April 2023

Supplemental Figure 4: Representative immunoblot demonstrating PARP1 cleavage in IMR32 cells in response to Lig3 siRNA knockdown.
Figure S1 from Kinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase
Authors: Peng Hongzhuang , Cassel Joel , McCracken Daniel S. , Prokop Jeremy W. , Sementino Eleonora , Cheung Mitchell , Collop Paul R. , Polo Alexander , Joshi Surbhi , Mandell Jacob P. , Ayyanathan Kasirajan , Hinds David , Malkowicz S. Bruce , Harbour J. William , Bowcock Anne M. , Salvino Joseph , Kennedy Eileen J. , Testa Joseph R. , Rauscher Frank J.
Published: April 2023

S1. BAP1 expression in mouse single cell datasets.
Supplemental Figure Legends from Elevated Slit2 Activity Impairs VEGF-Induced Angiogenesis and Tumor Neovascularization in EphA2-Deficient Endothelium
Authors: Youngblood Victoria , Wang Shan , Song Wenqiang , Walter Debra , Hwang Yoonha , Chen Jin , Brantley-Sieders Dana M.
Published: April 2023

Supplemental Figure Legends
Supplementary Data 2 from Suberoylanilide Hydroxamic Acid as a Radiosensitizer through Modulation of RAD51 Protein and Inhibition of Homology-Directed Repair in Multiple Myeloma
Authors: Chen Xufeng , Wong Patty , Radany Eric H. , Stark Jeremy M. , Laulier Corentin , Wong Jeffrey Y.C.
Published: April 2023

PDF file - 41K, Dose-dependent cytoxicity of SAHA on Multiple Myeloma cells in vitro. * and ** indicate significances (*Rho<0.05 and **Rho<0.01)
Supplementary Figure 1 from SPINDLIN1 Promotes Cancer Cell Proliferation through Activation of WNT/TCF-4 Signaling
Authors: Wang Jing-Xue , Zeng Quan , Chen Lin , Du Ji-Chao , Yan Xin-Long , Yuan Hong-Feng , Zhai Chao , Zhou Jun-Nian , Jia Ya-Li , Yue Wen , Pei Xue-Tao
Published: April 2023

PDF file - 2MB, Effect of SPINDLIN1 depletion on cancer cell proliferation and WNT/TCF-4 signaling. A. The siRNA interference sequence against SPINDLIN1 or an oligonucleotide control sequence was transfected into HeLa cells, and RT-PCR was used to examine the expression of SPINDLIN1, using �-ACTIN as an internal standard. B. HeLa cells treated with the same methods as A were used for the CCK-8 assay to analyze cell proliferation. The absorbance at 450 nm was monitored every 24 h over 7 d. N=6. C. Five hundred HeLa cells per well were treated with the same methods as A and were plated in 6-well plates and incubated for 2-3 weeks. Colonies were stained with crystal violet (top panels) and the numbers of colonies were counted (bottom panel). N=3, **p<0.01 compared to control (Student's t test). D. In HeLa cells, pTOPFlash was co-transfected with the siRNA interference sequence against SPINDLIN1 or the negative control sequence, and the pFOPFlash control vector was co-transfected with the siRNA interference sequence against SPINDLIN1. The TCF/�-CATENIN-responsive activity was expressed as relative luciferase activity, normalized to Renilla activity, and given as n-fold relative to the activity of control. Error bars indicate the means � SD. N=3, **p<0.01 compared with the level of OT+siRNA-SPINDLIN1 (Student's t test).
Supplementary Figure 3 from EWS/FLI1 Regulates EYA3 in Ewing Sarcoma via Modulation of miRNA-708, Resulting in Increased Cell Survival and Chemoresistance
Authors: Robin Tyler P. , Smith Anna , McKinsey Erin , Reaves Lisa , Jedlicka Paul , Ford Heide L.
Published: April 2023

PDF file - 17K, Expression of miR mimics in 293T cells as assessed by qRT-PCR
Supplementary Figure 3 from TNF-α Induces Epithelial–Mesenchymal Transition of Renal Cell Carcinoma Cells via a GSK3β-Dependent Mechanism
Authors: Ho Ming-Yi , Tang Shye-Jye , Chuang Mei-Jen , Cha Tai-Lung , Li Jing-Yao , Sun Guang-Huan , Sun Kuang-Hui
Published: April 2023

PDF file- 227K, Inactivation of GSK-3β was involved in the transformation, migration, and invasion of RCC cells.
Supplementary Table 1 and Supplementary Figures 1-5 from Stem Cell Marker Nestin Is Critical for TGF-β1-Mediated Tumor Progression in Pancreatic Cancer
Authors: Su Huei-Ting , Weng Ching-Chieh , Hsiao Pi-Jung , Chen Li-Hua , Kuo Tzu-Lei , Chen Yu-Wen , Kuo Kung-Kai , Cheng Kuang-Hung
Published: April 2023

PDF File - 33K, The primer sequences for RT-qPCR analysis of the indicated genes.
Supplementary Data figures and tables from The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells
Authors: Parasido Erika , Avetian George S. , Naeem Aisha , Graham Garrett , Pishvaian Michael , Glasgow Eric , Mudambi Shaila , Lee Yichien , Ihemelandu Chukwuemeka , Choudhry Muhammad , Peran Ivana , Banerjee Partha P. , Avantaggiati Maria Laura , Bryant Kirsten , Baldelli Elisa , Pierobon Mariaelena , Liotta Lance , Petricoin Emanuel , Fricke Stanley T. , Sebastian Aimy , Cozzitorto Joseph , Loots Gabriela G. , Kumar Deepak , Byers Stephen , Londin Eric , DiFeo Analisa , Narla Goutham , Winter Jordan , Brody Jonathan R. , Rodriguez Olga , Albanese Chris
Published: April 2023

Supplementary Data figures and tables Fig. S1. Genomic characterization of CR cells. Fig. S2. Karyotype analysis of CR cells. Fig. S3. Drug sensitivity profiles of CR cells. Fig. S4. Population doubling times of Parental and nab-paclitaxel resistant cells. Fig. S5. Nab-paclitaxel sensitivity of CR spheroids. Fig. S6. Dependency of CR cells on KRAS. Fig. S7. CR-based PDX tumors in mice. Fig. S8. Reverse Phase Proteomic analysis of Parental and nab-paclitaxel resistant cells. Fig. S9. Modulation of c-Myc and the effects on nab-paclitaxel sensitivity. Fig. S10. SMAP2 Responses. Table S1. Patient data Table S2. Gene mutations associated with nab-paclitaxel resistance